To investigate the relationship between microalbuminuria (MAU) and atrial fibrillation (AF) and to further evaluate whether the heart rate dependency of MAU in patients without AF is maintained in patients with a history of AF.
Introduction
Microalbuminuria (MAU) defined as a urinary albumin excretion (UAE) of 30 -300 mg/L is an accepted marker of generalized endothelial injury 1,2 and dysfunction. 3 It predicts progression to diabetic nephropathy 4, 5 and is closely related to vascular disease in ischaemic heart disease and diastolic dysfunction, 6 congestive heart failure, 7 or severe arterial hypertension. 8 In addition to its function as a marker of kidney damage, MAU represents an indirect window to monitor the status of the whole vasculature. 9 The pathophysiological mechanisms involved in transcapillary leakage of albumin might be related to an increased intraglomerular pressure in hypertension, 10 a general endothelial dysfunction leading to transgression of albumin 11 or an impaired arterial dilatory capacity in hypertensive but otherwise clinically healthy subjects. 12 High heart rate has been shown to be associated with cardiovascular complications as first described in 1945. 13 This applies to cardiovascular complications in the general population, 14, 15 in hypertensive individuals, 16 -18 in ischaemic heart disease, 19, 20 in heart failure, 21 and in diabetes. 22 Therefore, elevated heart rate has been proposed as a cardiovascular risk factor within the cardiovascular continuum of disease progression. 23 Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and increases the risk of cardiovascular mortality by approximately two-fold. 24, 25 The presence of hypertension accompanied by left ventricular hypertrophy and left atrial chamber dilatation is regarded as a cardiac risk factor for the development of AF. 26 In heart failure patients, new onset of AF can occur in 5-50% of cases depending on the severity of heart failure and is associated with higher heart rates and worse outcomes. 27 In patients without a history of AF, an association between heart rate and MAU has been described to occur independently of betablocker use and physical activity. 28 The global I-SEARCH study involved 1750 sites in 26 countries in a population of more than 20 000 hypertensive patients treated by cardiologists. 29 The primary objective was to study the relationship between cardiovascular risk factors and co-morbidities and MAU. Aim of the present analysis was to investigate the relationship between MAU and AF and to further evaluate whether the heart-rate dependency of MAU in patients without a history of AF is maintained in patients with a history of AF.
Methods Patients
The I-SEARCH study was an international observational study in male and female patients, aged 18 years or older with currently treated or newly diagnosed arterial hypertension, defined as a seated systolic/ diastolic blood pressure .140/90 mmHg at rest on the day of the study visit. 29 comprised the analysis population. Over the 6 month study period a total of 22 282 patients were screened, of whom 21 794 gave written informed consent to participate in the study. Of these, 744 patients failed to meet inclusion criteria or had missing entries on their case report form (CRF) with respect to cardiovascular history or to albumin and creatinine levels and thus were excluded from the study. The remaining 21 050 patients constituted the primary analysis population. For the present investigation 445 patients without data on AF history were excluded. Thus, 18 900 patients without a history of AF were compared with 1705 patients with a history of AF. Assignment to 'History of AF' was performed by the treating cardiologist and did not require AF at the time of inclusion in the study. At inclusion the heart rhythm was classified as sinus rhythm (SR) or not. In the latter case the actual rhythm was not further specified in the CRF.
Study design and procedures
At each study site, consecutive patients fulfilling eligibility criteria were invited to participate in the study. Once enrolled, the following measurements were carried out in each patient: heart rate, blood pressure, urine albumin and creatinine concentration, and waist and hip circumference. In order to achieve reliable and comparable results, blood pressure and heart rate were measured by the treating physician twice in a supine position after 5 min of rest, according to the consensus statement of the European Society of Hypertension and the American College of Cardiology. 30, 31 To ensure consistency between study sites, all centres performed semi-quantitative dipstick screening for MAU with the same reagent strips (Microalbustix, Bayer Leverkusen, Germany) and followed a standardized sample collection and testing procedure. The resolution of the reagent strips was 10, 30, 80, or 150 mg albumin/L urine. Abnormal urine albumin excretion (MAU) was defined as a dipstick result of 30, 80, or 150 mg albumin/L urine, whereas a result of 10 mg/L was defined as normal UAE. Level of urinary creatinine excretion (10, 50, 100, 200, and 300 mg/L) was determined. Glomerular filtration rate (eGFR) was estimated using the Cockcroft formula. 32 Moreover, demographic data, data on cardiovascular history, presence of cardiovascular risk factors, co-morbidities, symptoms and signs of cardiovascular disease, and current chronic drug therapy were collected. Figure 1 ). For risk analyses with MAU as outcome variable, multivariable unconditional logistic regression analysis was performed. Variables with ,10% of missing data were selected by pathophysiological consideration, and wellknown risk-factors were included. Due to its likely important pathophysiological role, eGFR was included in multivariable analysis despite 28% of missing data. To facilitate interpretation and presentation of data, continuous variables were categorized according to clinically relevant classes. Nevertheless, additional analysis was performed using these data as continuous variables. The goodness-of-fit Figure 1 Prevalence of microalbuminuria at different resting heart rates (b.p.m.) in patients with and without a history of atrial fibrillation. The significant P-value indicates that the association between MAU and heart rate remains strong after adjusting for a history of AF. The prevalence of MAU was higher in patients with a history of atrial fibrillation.
Statistical methods
was tested with Hosmer-Lemeshow test. For all models mentioned below, the test results were not significant. Interaction of predictor variables was checked within the appropriate model. Odds ratios are given with 95% confidence intervals. All statistical analyses were performed with SPSS version 17.0 (SPSS Inc., Chicago, IL, USA).
Results
Study population and physician profile of the I-SEARCH study have been described elsewhere. 29 Patients without a history of AF (n ¼ 18 900) were in 98.3% of cases in SR. Patients with a history of AF (n ¼ 1705) were in only 54.8% of cases in SR (P , 0.001). The demographic data as well as cardiovascular risk factors and medical treatments are given in Table 1 . As expected, patients with a history of AF were older, more often male, and more diseased.
For patients with and without a history of AF, Figure 1 shows the prevalence of MAU (dip-stick result 30 mg/L) at different heart rates. In both groups, the prevalence of MAU was higher at higher heart rate (P , 0.001). There was no significant interaction between heart rate (as continuous variable) and history of AF (P ¼ 0.221). Prevalence of MAU was higher in the population with a history of AF (65.6 vs. 57.8%, P , 0.001, Table 1 ). MAU amounted to more than 80% in individuals with a heart rate of above 100 b.p.m. and a history of AF. Figure 2 shows the proportion of patients with different degrees of UAE at different heart rates. Results are shown for patients with and without a history of AF. In the absence of AF, the proportion of patients with little or without MAU (UAE 30 mg/L) was lower at higher heart rates. Similar results were observed in patients with a history of AF. Vice versa, the proportion of patients with higher levels of UAE was increased at higher heart rate (P , 0.001). Figure 3 shows the prevalence of MAU at different heart rates and eGFRs in patients with and without a history of AF. In both groups, a lower eGFR and a higher heart rate appear to be linked with a higher prevalence of MAU (P , 0.001). However, in the presence of a markedly impaired renal function, (i.e. eGFR ,30 mL/min) the influence of heart rate on MAU was abolished.
There were no patients with a history of AF, a resting heart rate .100 b.p.m. and an eGFR ,30 mL/min. Statistical analysis revealed no significant interaction between heart rate (as continuous variable) and eGFR (P ¼ 0.355 for the group without history of AF and P ¼ 0.136 for the group with history of AF).
Using multivariable regression analysis, history of AF, male gender, systolic blood pressure .160 mmHg, diastolic blood pressure .90 mmHg, heart rate .80/min, and eGFR 80 mL/ min, as well as the presence of heart failure, coronary artery disease, history of stroke, and diabetes mellitus were associated Figure 2 Proportion of patients with different levels of microalbuminuria (UAE, urine albumin excretion) at different resting heart rates. Both, data from the group without (left) and the group with a history of atrial fibrillation (right) are given. Higher heart rates were associated with higher UAE, independent of rhythm. This finding was even more pronounced in patients with a history of atrial fibrillation. Figure 3 Prevalence of microalbuminuria (MAU) at different heart rates and levels of glomerular filtration rate (eGFR). Both, data from the group without (left) and the group with a history of atrial fibrillation (right) are given. A lower estimated glomerular filtration rate appears to be linked with an increased prevalence of microalbuminuria (P , 0.001), a relationship that seemed to be heart-rate dependent. However, in the presence of a markedly impaired renal function (i.e. eGFR , 30 mL), the influence of heart rate on microalbuminuria was abolished.
with MAU ( Table 2) . 28, 29 In contrast, the use of several drugs affecting the cardiovascular system was not associated with significantly increased or decreased odds for MAU. The results were similar when the continuous variables were included in the model without categorization: The odds ratio for MAU was 1.015 (95% CI: 1.012 -1.018) per increase in heart rate by 1 b.p.m., 1.003 (1.002 -1.005) for a decrease in eGFR by 1 mL/min, and 1.006 (1.003 -1.008) and 1.007 (1.003 -1.011) for an increase in systolic and diastolic blood pressure by 1 mmHg, respectively (P , 0.001 for all). An increase in heart rate was associated with an increased prevalence of MAU, whether a history of AF was present or not. Statistically, there was no significant interaction between history of AF and heart rate.
To illustrate this multivariable analysis was repeated for patients with and without a history of AF ( Table 3 ). In both groups male gender, a higher diastolic blood pressure, higher heart rate, and the presence of diabetes mellitus were associated with significantly higher odds for MAU. When the continuous variables were included in the model without categorization, the odds ratio for MAU in the group of patients without a history of AF was 1.014 (1.011-1.018) per increase in heart rate by 1 b.p.m., 1.003 (1.002 -1.005) for a decrease in eGFR by 1 mL/min, and 1.006 (1.004 -1.009) and 1.006 (1.002 -1.010) for an increase in systolic and diastolic blood pressure by 1 mmHg, respectively (P , 0.001 for all). Similarly, the odds ratio for MAU in patients with a history of AF was 1.021 (1.011-1.031, P , 0.001) per increase in heart rate by 1 b.p.m., and 1.018 (1.005-1.032, P ¼ 0.007) for an increase in diastolic blood pressure by 1 mmHg, respectively, whereas the odds for MAU were not significantly different from 1 with regard to the other continuous variables.
Discussion
Microalbuminuria is accepted as a risk indicator for cardiovascular complications and progression of renal disease and is closely associated with blood pressure levels. 1, 4, 5 Recently, evidence has been provided that MAU is associated with an elevated heart rate independent of the use of beta-blockers. 28 An elevated heart rate enhances the magnitude and frequency of the tensile stress imposed on the arterial wall and also increases systolic flow-induced shear stress. Both factors are likely to promote atherosclerosis. (For detailed review see Giannoglou et al.
33
) The association between heart rate, renal, and cardiac end organ damage (in this case AF) as determined by MAU had not been investigated so far.
The I-SEARCH study was a global international study in hypertensive patients in 26 countries. The prevalence of MAU was higher than previously reported for hypertensive populations 34 or for patients with diabetes without albuminuria at entry as observed in the DEMAND study. 35 For this reason and because also patients with coronary heart disease were included and almost 20% had an eGFR of ,60 mL/min, the I-SEARCH patients apparently represent a population at particularly high risk. 29 In this population, the prevalence of MAU was closely associated with resting heart rate. 28 When adjusted for other cardiac risk factors such as pre-existing cardiac disease, diabetes, age, gender, as well as concomitant medical treatment, heart rate was still an independent predictor of MAU. This finding of heart rate being an independent predictor of MAU possibly indicates that the number of pressure waves passing the renal arteries and imposing load onto the glomerulus might facilitate damage to the renal filter thereby causing MAU. In the present analysis, it was shown that a history of AF is associated with an increased prevalence of MAU ( Table 2) . Irrespective of a history of AF, a higher heart rate is associated with a higher prevalence of MAU. In patients with a history of AF, prevalence of MAU at the same heart rate was about 10% higher, when compared with patients without AF (Figure 1) . Multivariable analysis, including other factors contributing to MAU 29 such as systolic or diastolic blood pressure, concomitant medication, and presence of coronary artery disease or heart failure, revealed that a higher heart rate is independently associated with a higher odds for MAU in patients without and with a history of AF. Thus, the study shows an association of renal and cardiac end organ damage and further supports the hypothesis that MAU is an indicator of a generalized damage to the heart and the vasculature. In previous studies, the predictors of AF in the hypertensive populations were age, left ventricular mass, atrial diameter, and left ventricular hypertrophy on ECG indicated by the Sokolow index. 26, 27 Renal impairment and in particular MAU have not with subclinical atherosclerosis as judged from carotid intimamedia thickness. 36 These results and data presented herein suggest that early vascular and early renal end organ damage might be associated if not causally linked with the occurrence of AF. Mechanistically, it is reasonable to assume that endothelial dysfunction as reflected by MAU might induce atrial ischaemia thereby favouring the occurrence of AF. 37 On the other hand, the irregularity of pulse waves due to AF might further impair the capillary filter thereby promoting vascular damage. Interestingly, it was recently shown in atrial tissue of patients and in an atrial tachycardia pig model that a high atrial rate is associated with an increased expression of vascular cell adhesion molecules (VCAMs) and intercellular adhesion molecules (ICAMs) as well as other prothrombotic proteins on endothelial cells. 38 In line with these observations, an association of AF with C-reactive protein concentrations was reported. 39 Signs of impaired endothelial function have been reported in patients with AF, which improved within 1 month after restoration of SR by cardioversion. 40 In humans, acute AF is associated with decreased cardiac nitric oxide production. 41 Therefore, AF itself might have an impact on endothelial function, organ perfusion, and neuroendocrine activation. Already in 1902 MacKenzie 42 recognized the loss of effective atrial contraction in 'heart irregularity', and Skinner et al. 43 described the adverse haemodynamic consequences of AF in 1964. The irregularity of ventricular cycle length during AF augments pulmonary wedge pressure and right atrial pressure and decreases cardiac output. 44 Furthermore, micro-embolization in the peripheral circulation may occur. Taken together, these findings provide an interesting pathophysiological concept for the link of AF and MAU and may explain the increased prevalence of MAU in high-risk hypertensive individuals with a history AF compared with those without the arrhythmia.
Limitations
A limitation of the present study is the cross-sectional design. Therefore (and because of a certain degree of missing data) the results are rather hypothesis generating and do not indicate causal relationship. However, I-SEARCH was a study based on patients with hypertension mainly under the ambulatory care of cardiologists in private practice. Thus the study closely reflects daily clinical practice where MAU is tested once on an occasional level, a methodology which has also been applied in various population-based studies. In addition, the study involved more than 21 000 patients in 26 countries across the world. Therefore, the I-SEARCH program is among the global investigations the largest screening program for MAU ever done. Whether a single patient has a 'history of AF' or not was judged by the treating cardiologist. At the time of presentation, ECG was not documented in all patients. No further information on the type or duration of AF was collected, since the study was designed to evaluate high-risk hypertensive patients and not specifically AF patients. The same holds true for collection of echocardiographic parameters or serum markers of inflammation or oxidative stress.
However, the standardized procedure for determining MAU, the large sample size, and the global nature of this population Results from multivariable unconditional logistic regression analysis (abbreviations as in Table 2 ). Data about all variables were available in 12 972 of 18 900 patients (68.6%) without, and in 1264 of 1705 patients (74.1%) with a history of atrial fibrillation.
with its close vicinity to daily practice might allow interpreting the results with some confidence.
Perspectives
The practical consequences of these data are that screening for MAU should be performed in every hypertensive patient in particular when end organ damage is suspected such as AF (this study) and subclinical atherosclerosis. 36 Although screening for MAU is recommended by international treatment guidelines for hypertensive subjects, data from Europe show that in daily practice this is performed in only 2% of the cases. 45 Furthermore, heart rate as simple measure should be taken under standardized conditions in hypertensive patients to further evaluate risk. 30 
Conclusions
In summary, higher heart rates and AF are associated with MAU. Therefore, heart rate might be a predictor of both cardiovascular and renal damage in high-risk populations. Atrial fibrillation might be either considered as a cause of end organ damage or as a result from prolonged vascular damage, both indicated by MAU.
Since the I-SEARCH data have demonstrated that MAU is very common in hypertensive patients at high risk, this simple dipstick urine analysis should be performed in any high-risk patients in order to determine vascular end organ damage and to implement effective primary and secondary prevention measures.
